JP2017505330A5 - - Google Patents

Download PDF

Info

Publication number
JP2017505330A5
JP2017505330A5 JP2016550646A JP2016550646A JP2017505330A5 JP 2017505330 A5 JP2017505330 A5 JP 2017505330A5 JP 2016550646 A JP2016550646 A JP 2016550646A JP 2016550646 A JP2016550646 A JP 2016550646A JP 2017505330 A5 JP2017505330 A5 JP 2017505330A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
microcrystalline cellulose
compound
oil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016550646A
Other languages
English (en)
Japanese (ja)
Other versions
JP6633531B2 (ja
JP2017505330A (ja
Filing date
Publication date
Priority claimed from GB201402070A external-priority patent/GB201402070D0/en
Application filed filed Critical
Publication of JP2017505330A publication Critical patent/JP2017505330A/ja
Publication of JP2017505330A5 publication Critical patent/JP2017505330A5/ja
Application granted granted Critical
Publication of JP6633531B2 publication Critical patent/JP6633531B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016550646A 2014-02-07 2015-02-04 炎症性障害の治療のための医薬組成物 Active JP6633531B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1402070.5 2014-02-07
GB201402070A GB201402070D0 (en) 2014-02-07 2014-02-07 Pharmaceutical compositions for the treatment of inflammatory disorders
PCT/EP2015/052239 WO2015117980A1 (en) 2014-02-07 2015-02-04 Pharmaceutical compositions for the treatment of inflammatory disorders

Publications (3)

Publication Number Publication Date
JP2017505330A JP2017505330A (ja) 2017-02-16
JP2017505330A5 true JP2017505330A5 (enExample) 2018-03-15
JP6633531B2 JP6633531B2 (ja) 2020-01-22

Family

ID=50390571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550646A Active JP6633531B2 (ja) 2014-02-07 2015-02-04 炎症性障害の治療のための医薬組成物

Country Status (14)

Country Link
US (1) US10493158B2 (enExample)
EP (1) EP3102213B1 (enExample)
JP (1) JP6633531B2 (enExample)
AR (1) AR099306A1 (enExample)
AU (1) AU2015215044B2 (enExample)
CA (1) CA2938217C (enExample)
DK (1) DK3102213T3 (enExample)
ES (1) ES2788671T3 (enExample)
GB (1) GB201402070D0 (enExample)
HR (1) HRP20200605T1 (enExample)
NZ (1) NZ722403A (enExample)
TW (1) TWI697330B (enExample)
UY (1) UY35985A (enExample)
WO (1) WO2015117980A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2699580T3 (enExample) 2014-01-24 2018-02-24
GB201402071D0 (en) 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
CN105111206B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105198877B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105218539B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198880B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198879B (zh) * 2015-09-18 2017-09-22 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105198878B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105111207B (zh) * 2015-09-18 2017-07-25 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198876B (zh) * 2015-09-18 2017-09-29 上海宣创生物科技有限公司 一种环丙烷甲酰胺衍生物h晶型及其制备方法
CN108366958A (zh) * 2015-11-30 2018-08-03 安那卡药品公司 用于治疗炎症相关病症的局部药物制剂
KR20180120273A (ko) * 2016-03-21 2018-11-05 크리스탈 파마테크 씨오., 엘티디. Jak 관련 질병 예방 또는 치료용 약물의 염산 결정성 형태 및 이의 제조 방법
CA3043396A1 (en) 2016-11-10 2018-05-17 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
GB201702603D0 (en) 2017-02-17 2017-04-05 Galápagos Nv Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar) * 2017-03-14 2019-01-30 Gilead Sciences Inc تركيبات صيدلية تتضمن مثبط jak
KR102738945B1 (ko) 2018-03-01 2024-12-04 아스트라제네카 에이비이 (2s)-n-{(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸}-1,4-옥사제판-2-카복스아미드를 포함하는 약학 조성물
GB201808575D0 (en) 2018-05-24 2018-07-11 Galapagos Nv Methods for the treatment of psoriatic arthrits
KR20210032431A (ko) 2018-07-17 2021-03-24 인스메드 인코포레이티드 루푸스 신염을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카복스아미드
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
CN120584108A (zh) 2023-01-06 2025-09-02 英斯梅德股份有限公司 新型可逆dpp1抑制剂及其用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2228451T3 (es) 1999-01-29 2005-04-16 Chugai Seiyaku Kabushiki Kaisha Promotores de condrogenesis y derivados de indolin-2-ona.
JPWO2002087620A1 (ja) 2001-04-27 2004-08-12 中外製薬株式会社 軟骨形成促進剤
US6514989B1 (en) 2001-07-20 2003-02-04 Hoffmann-La Roche Inc. Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
DE602004001676T2 (de) 2003-02-14 2007-08-30 Pfizer Products Inc., Groton Triazolo-Pyridine als entzündungshemmende Verbindungen
US20050222171A1 (en) 2004-01-22 2005-10-06 Guido Bold Organic compounds
EP1759203A2 (en) 2004-06-21 2007-03-07 Galapagos N.V. Methods and means for treatment of osteoarthritis
MX2007002050A (es) 2004-08-18 2007-03-29 Pharmacia & Upjohn Co Llc Compuestos de triazolopiridina.
WO2006038116A2 (en) 2004-10-07 2006-04-13 Warner-Lambert Company Llc Triazolopyridine derivatives as antibacterial agents
GB0515026D0 (en) 2005-07-21 2005-08-31 Novartis Ag Organic compounds
KR20130016386A (ko) * 2005-08-10 2013-02-14 시오노기세이야쿠가부시키가이샤 구강내 붕괴 정제
ES2549862T3 (es) 2006-08-30 2015-11-02 Cellzome Limited Derivados de triazol como inhibidores de quinasa
PE20090370A1 (es) 2007-06-05 2009-04-30 Takeda Pharmaceutical Derivados de heterociclo fusionado como inhibidores de quinasa
AU2008277628B2 (en) 2007-07-18 2012-03-15 Novartis Ag Bicyclic heteroaryl compounds and their use as kinase inhibitors
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
AU2008291075A1 (en) 2007-08-31 2009-03-05 Merck Serono S.A. Triazolopyridine compounds and their use as ask inhibitors
GB0719803D0 (en) 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
KR20110031475A (ko) 2008-06-20 2011-03-28 제넨테크, 인크. 트리아졸로피리딘 jak 억제제 화합물 및 방법
JO3041B1 (ar) * 2008-07-25 2016-09-05 Galapagos Nv مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010188A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases.
WO2010010187A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en) 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010186A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010189A1 (en) 2008-07-25 2010-01-28 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CN102459258B (zh) 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
TWI462920B (zh) * 2009-06-26 2014-12-01 葛萊伯格有限公司 用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) 2009-06-26 2016-09-05 Galapagos Nv مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
MA37775A1 (fr) 2012-06-22 2017-04-28 Galapagos Nv Aminotriazolopyridine pour l'utilisation dans le traitement de l'inflammation, et compositions pharmaceutiques associées
JP6041823B2 (ja) * 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
GB201402071D0 (en) * 2014-02-07 2014-03-26 Galapagos Nv Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2017505330A5 (enExample)
HRP20200605T1 (hr) Farmaceutske kompozicije za liječenje inflamatornih poremećaja
JP2018507200A5 (enExample)
JP2009509962A5 (enExample)
JP2016537347A5 (enExample)
JP6245677B2 (ja) 口腔内崩壊錠
ES2736155T3 (es) Comprimidos de otilonio por compresión directa
SG10201407947WA (en) Compressible-coated pharmaceutical compositions and tablets and methods of manufacture
EP3446686A1 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate
KR102024699B1 (ko) 클로피도그렐 및 아스피린을 포함하는 복합제제
JP2007503414A5 (enExample)
RU2006133902A (ru) Твердые препаративные формы оспемифена
ES2759801T3 (es) Formulación gastro-resistente que contiene posaconazol
JP2018501217A5 (enExample)
HK1205456A1 (en) A solid oral pharmaceutical formulation containing ticagrelor
JP2018503611A5 (enExample)
EP3332769A1 (en) Solid oral pharmaceutical compositions of ticagrelor
JP2021512869A5 (enExample)
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
WO2016079687A1 (en) Oral pharmaceutical composition of teriflunomide
KR20140045925A (ko) 선택적 세로토닌 재흡수 억제제의 방출조절형 약제학적 조성물
WO2016189406A1 (en) Pharmaceutical composition of teriflunomide
WO2021091510A1 (en) A capsule comprising eltrombopag olamine
JP2019156845A (ja) 抗菌物質を含む安定な医薬組成物
JP5910311B2 (ja) 医薬錠剤およびその製造方法